Gastroenterologists Using Biologics for Crohn's Disease Treatment

Source: PharmaManufacturing.com

Mar 06, 2013

GenEngNews.com

Although there have been no significant changes with regard to biologic treatment and Crohn's disease patients with active disease since 2012, surveyed gastroenterologist data indicate a significant 43 percent increase in biologic treatment among CD patients in remission since 2012, suggesting that biologic agents are increasingly prescribed to maintain the state of remission. The increase in biologic share among the CD patients in remission is most likely at the cost of 5-ASA treatment, which has experienced a 15 percent decline during the same time period, according to the surveyed gastroenterologists. Furthermore, Abbott's adalimumab and UCB's certolizumab are driving the escalation of biologic treatment among the remission population, with both agents experiencing significant patient share growth in this group over the past year.The recently published TreatmentTrends: Crohn's Disease report also reveals that three-quarters of the surveyed physicians feel that there is a high unmet need for new agents to treat Crohn's disease, often citing that they are challenged by the adverse events/side effects of current treatment and that achieving and maintaining remission and avoiding treatment failures are also issues. With regard to products in development, nearly one-third of gastroenterologists claim to be aware of products in development for the treatment of CD. Read the full story here. 
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments